Literature DB >> 17621952

Antimicrobial peptides: natural effectors of the innate immune system.

Katherine Radek1, Richard Gallo.   

Abstract

Antimicrobial peptides (AMPs) are an evolutionarily conserved component of the innate immune system that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. The efficiency of host defense via AMPs derives from the ability of these peptides to quickly identify and eradicate foreign pathogens through precise biochemical mechanisms. Recent advances in this field have expanded the repertoire of activities for AMPs to include immunostimulatory and immunomodulatory capacity as a catalyst for secondary host defense mechanisms. Further scrutiny of the biochemical and regulatory mechanisms of AMPs will lead to novel alternative approaches to the treatment of human pathogenic disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621952     DOI: 10.1007/s00281-007-0064-5

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   11.759


  181 in total

Review 1.  Antibacterial and antifungal peptides derived from chromogranins and proenkephalin-A. From structural to biological aspects.

Authors:  M H Metz-Boutigue; K Lugardon; Y Goumon; R Raffner; J M Strub; D Aunis
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

Review 2.  Host-defense antimicrobial peptides: importance of structure for activity.

Authors:  N Sitaram; R Nagaraj
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

3.  Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides.

Authors:  Per-Gøran Krüger; Sushil K Mahata; Karen B Helle
Journal:  Regul Pept       Date:  2003-06-15

Review 4.  An unexpected role for hypoxic response: oxygenation and inflammation.

Authors:  Carole Peyssonaux; Randall S Johnson
Journal:  Cell Cycle       Date:  2004-02       Impact factor: 4.534

5.  Structural organization of the bovine cathelicidin gene family and identification of a novel member.

Authors:  M Scocchi; S Wang; M Zanetti
Journal:  FEBS Lett       Date:  1997-11-17       Impact factor: 4.124

6.  Alternative splicing of the proadrenomedullin gene results in differential expression of gene products.

Authors:  A Martínez; D L Hodge; M Garayoa; H A Young; F Cuttitta
Journal:  J Mol Endocrinol       Date:  2001-08       Impact factor: 5.098

7.  Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides.

Authors:  A Peschel; M Otto; R W Jack; H Kalbacher; G Jung; F Götz
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

8.  Antimicrobial effects of alpha-MSH peptides.

Authors:  M Cutuli; S Cristiani; J M Lipton; A Catania
Journal:  J Leukoc Biol       Date:  2000-02       Impact factor: 4.962

9.  The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.

Authors:  Johan D Heilborn; Margareta Frohm Nilsson; Gunnar Kratz; Günther Weber; Ole Sørensen; Niels Borregaard; Mona Ståhle-Bäckdahl
Journal:  J Invest Dermatol       Date:  2003-03       Impact factor: 8.551

10.  Human neutrophil defensin and serpins form complexes and inactivate each other.

Authors:  A V Panyutich; P S Hiemstra; S van Wetering; T Ganz
Journal:  Am J Respir Cell Mol Biol       Date:  1995-03       Impact factor: 6.914

View more
  78 in total

Review 1.  Antimicrobial anxiety: the impact of stress on antimicrobial immunity.

Authors:  Katherine A Radek
Journal:  J Leukoc Biol       Date:  2010-05-04       Impact factor: 4.962

Review 2.  Toll-like receptors in ocular surface disease.

Authors:  Rachel L Redfern; Alison M McDermott
Journal:  Exp Eye Res       Date:  2010-03-24       Impact factor: 3.467

3.  Innate barriers against infection and associated disorders.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Drug Discov Today Dis Mech       Date:  2008-06-01

4.  Molecular Design, Structural Analysis and Antifungal Activity of Derivatives of Peptide CGA-N46.

Authors:  Rui-Fang Li; Zhi-Fang Lu; Ya-Nan Sun; Shi-Hua Chen; Yan-Jie Yi; Hui-Ru Zhang; Shuo-Ye Yang; Guang-Hai Yu; Liang Huang; Chao-Nan Li
Journal:  Interdiscip Sci       Date:  2016-05-10       Impact factor: 2.233

5.  Bioactivity and the first transmission electron microscopy immunogold studies of short de novo-designed antimicrobial peptides.

Authors:  Marisa Ann Azad; Heidi Esther Katrina Huttunen-Hennelly; Cynthia Ross Friedman
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

Review 6.  Cholinergic regulation of keratinocyte innate immunity and permeability barrier integrity: new perspectives in epidermal immunity and disease.

Authors:  Brenda J Curtis; Katherine A Radek
Journal:  J Invest Dermatol       Date:  2011-09-15       Impact factor: 8.551

Review 7.  Defensins as anti-inflammatory compounds and mucosal adjuvants.

Authors:  Karl G Kohlgraf; Lindsey C Pingel; Deborah E Dietrich; Kim A Brogden
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

8.  Natural molecules induce and synergize to boost expression of the human antimicrobial peptide β-defensin-3.

Authors:  Emmanuel Sechet; Erica Telford; Clément Bonamy; Philippe J Sansonetti; Brice Sperandio
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

Review 9.  The outer frontier: the importance of lipid metabolism in the skin.

Authors:  Kenneth R Feingold
Journal:  J Lipid Res       Date:  2008-10-31       Impact factor: 5.922

10.  Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.

Authors:  Ingrid Arijs; Gert De Hertogh; Katleen Lemaire; Roel Quintens; Leentje Van Lommel; Kristel Van Steen; Peter Leemans; Isabelle Cleynen; Gert Van Assche; Séverine Vermeire; Karel Geboes; Frans Schuit; Paul Rutgeerts
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.